Gladstone Institutional Advisory LLC lifted its position in Veru Inc. (NASDAQ:VERU – Free Report) by 52.7% in the 4th quarter, according to the company in its most recent filing with the Securities ...
NeuroPace Inc. recently announced that it has entered into a stock purchase agreement with KCK Ltd. The agreement, dated February 13, 2025, outlines the Company’s commitment to repurchase all shares ...
Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...
Dan Veru, CIO at Palisade Capital, says tariffs are negotiation tools, with companies adapting, though lower-margin ...
Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...
Discover Veru Inc.'s latest Q1 2025 updates on enobosarm & sabizabulin trials, financials, & strategic pivots in cardiometabolic and inflammation treatment.
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Ducommun Incorporated (NYSE: DCO) ("Ducommun” or the "Company”) today announced that it plans to release the Company's 2024 fourth quarter financial results on February 27, 2025, prior to the stock ...
Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...